Tvardi Therapeutics stock analysis
Want to see TVRD full AI Analyst Report?
Tvardi Therapeutics (TVRD) Stock Price & Analysis
TVRD Stock Chart & Stats
- Day’s Range
- $0.90 - $1.00
- 52-Week Range
- $0.77 - $5.69
- Previous Close
- $0.95
- Volume
- N/A
- Average Volume (3M)
- 286.18K
- Market Cap
- $12.64M
- Enterprise Value
- -$6.34M
- Total Cash (Recent Filing)
- $22.27M
- Total Debt (Recent Filing)
- $116.00K
- Price to Earnings (P/E)
- ―
- Beta
- 0.91
- Next Earnings
- Apr 06, 2027 (Est.)
- EPS Estimate
- -0.46
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
FDA-supported Phase 2 Planning
FDA feedback reduces uncertainty around the nonclinical package and provides a clearer framework for TTI-109’s Phase 2 development. This is a meaningful regulatory milestone that can improve execution readiness, although clinical safety and efficacy remain unproven.
Low Current Leverage
Very low debt limits fixed financial obligations and reduces balance-sheet pressure while Tvardi advances its pipeline. Positive equity also provides a stronger current capital position than in prior periods, although the company remains dependent on external funding.
Reduced Cash Burn
The substantial reduction in annual operating cash burn indicates better spending discipline relative to the peak consumption years. Lower burn can extend the company’s ability to fund development activities, even though cash generation has not yet become positive.
Bears Say
No Current Commercial Revenue
The move to zero revenue shows that Tvardi currently lacks recurring commercial traction and remains reliant on pipeline progress rather than an established revenue base. Continued net losses further limit internal funding capacity and increase dependence on future financing.
Persistent Negative Cash Generation
Ongoing operating and free-cash-flow deficits require Tvardi to fund research and development through its existing resources or external capital. This weakens financial resilience and can constrain development flexibility if funding conditions become less supportive.
Volatile Capitalization History
The large swings in equity indicate a historically unstable capitalization profile and significant financing activity typical of a development-stage biotech. Although current leverage is low, this history signals that future pipeline investment may continue to depend on capital access.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
What is Tvardi Therapeutics’s market cap?
When is Tvardi Therapeutics’s upcoming earnings report date?
How were Tvardi Therapeutics’s earnings last quarter?
Is Tvardi Therapeutics overvalued?
Does Tvardi Therapeutics pay dividends?
What is Tvardi Therapeutics’s EPS estimate?
How many shares outstanding does Tvardi Therapeutics have?
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tvardi Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Imran Alibhai
- Employees
- 12
- Website
- tvarditherapeutics.com
- Address
- 3 Sugar Creek Center Boulevard, Sugar Land, TX, 77478, US
Tvardi Therapeutics (TVRD) Earnings & Revenues
TVRD Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted a strategic focus on a promising NP program with potential for significant clinical and commercial success. However, challenges with KORSUVA revenue and increased R&D expenses were notable concerns.
View all TVRD earnings summariesTVRD Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |











